Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Somatic mutation genotyping and phosphatase and tensin homolog immunohistochemistry results by oestrogen receptor and progesterone receptor status and treatment arm

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

   PTEN low PIK3CA/ERBB mutated and/or PTEN lowa
Patient group Total no. of patients No. of patients (%) No. of patients (%)
ER status
 Negative 19 6 (31.6) 11 (57.9)
 Positive 26 8 (30.8) 14 (53.8)
PR status
 Negative 29 11 (37.9) 17 (58.6)
 Positive 16 3 (18.8) 8 (50)
Treatment arm
 TCL 6 2 (33.3) 4 (66.7)
 TCH 21 7 (33.3) 13 (61.9)
 TCHL 18 5 (31.3) 8 (44.4)
  1. Abbreviations: ER Oestrogen receptor, PR Progesterone receptor, TCH Docetaxel, carboplatin, and trastuzumab, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib, TCL Docetaxel, carboplatin, lapatinib
  2. Association of low PTEN expression and combined low PTEN expression and PIK3CA/ERBB family mutations (i.e., PI3K pathway activation) with ER and PR status. The mutation frequency in each treatment arm is also shown
  3. aBecause of mutation overlap, these numbers/percentages may not be a sum of PIK3CA and ERBB mutated